Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • For authors
    • Instructions for authors
    • Submit a manuscript
    • Author FAQs
    • Open access
    • COVID-19 submission information
  • Alerts
  • Podcasts
  • Subscriptions

Self-titration of inhaled corticosteroid and β2-agonist in response to symptoms in mild asthma: a pre-specified analysis from the PRACTICAL randomised controlled trial

Christina Baggott, Jo Hardy, Jenny Sparks, Mark Holliday, Daniela Hall, Alexandra Vohlidkova, Robert J. Hancox, Mark Weatherall, James Fingleton, Richard Beasley on behalf of the PRACTICAL Study Team
European Respiratory Journal 2020 56: 2000170; DOI: 10.1183/13993003.00170-2020
Christina Baggott
1Medical Research Institute of New Zealand, Wellington, New Zealand
2School of Biological Sciences, Victoria University of Wellington, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Christina Baggott
Jo Hardy
1Medical Research Institute of New Zealand, Wellington, New Zealand
2School of Biological Sciences, Victoria University of Wellington, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jo Hardy
Jenny Sparks
1Medical Research Institute of New Zealand, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Jenny Sparks
Mark Holliday
1Medical Research Institute of New Zealand, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mark Holliday
Daniela Hall
1Medical Research Institute of New Zealand, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Daniela Hall
Alexandra Vohlidkova
1Medical Research Institute of New Zealand, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Alexandra Vohlidkova
Robert J. Hancox
3Dept of Preventive and Social Medicine, University of Otago, Dunedin, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Robert J. Hancox
Mark Weatherall
4Dept of Medicine, University of Otago, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mark Weatherall
James Fingleton
1Medical Research Institute of New Zealand, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for James Fingleton
Richard Beasley
1Medical Research Institute of New Zealand, Wellington, New Zealand
2School of Biological Sciences, Victoria University of Wellington, Wellington, New Zealand
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Richard Beasley
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Introduction In mild asthma, as-needed budesonide–formoterol is superior or noninferior to maintenance budesonide plus as-needed short-acting β2-agonist in reducing severe exacerbations. In this pre-specified analysis, we investigated patterns of inhaled corticosteroid (ICS) and β2-agonist use in PRACTICAL, a randomised controlled trial.

Methods Participants were randomised 1:1 to as-needed budesonide–formoterol (200/6 μg Turbuhaler, one actuation) or maintenance budesonide (200 μg Turbuhaler, one actuation twice a day) with as-needed terbutaline (250 μg, two actuations) for 52 weeks. 110 participants had electronic monitors attached to their study inhalers which captured the time and date of every actuation. Key outcome measures were patterns of ICS and β2-agonist use. One actuation of budesonide–formoterol was considered to be an equivalent bronchodilator dose as two actuations of terbutaline.

Results Participants randomised to as-needed budesonide–formoterol had more days with no ICS use compared with maintenance budesonide (median total days of no use 156 versus 22 days, respectively), lower median daily budesonide dose (164 versus 328 μg, respectively) and a greater median number of days of ≥4 budesonide actuations (4 versus 1 days, respectively). Participants randomised to as-needed budesonide–formoterol took higher equivalent doses of β2-agonist both overall (median number of actuations 0.8 versus 0.3 per day, respectively) and in response to worsening asthma (total number of “overuse days” of >8 or >16 actuations of budesonide–formoterol or terbutaline 33 versus 10 days, respectively).

Conclusions The timing of ICS dose when self-titrated to β2-agonist use is more important than total ICS dose in reducing severe exacerbation risk in mild asthma, when associated with greater overall use of as-needed β2-agonist.

Abstract

In mild asthma, the timing of the ICS dose, when self-titrated through the vehicle of β2-agonist reliever use, is more important than total ICS dose in reducing severe exacerbation risk, when associated with greater overall as-needed β2-agonist use https://bit.ly/2Zs5CJV

Footnotes

  • This article has supplementary material available from erj.ersjournals.com

  • De-identified individual participant data collected during the PRACTICAL trial (Australian New Zealand Clinical Trials Registry identifier ACTRN12616000377437) will be shared beginning 2 years after article publication with no end date. These data will be available to researchers who provide a methodologically sound proposal for the purposes of achieving specific aims outlined in that proposal. Proposals should be directed to Richard Beasley via e-mail (richard.beasley{at}mrinz.ac.nz) and will be reviewed by the PRACTICAL study management committee. Requests to access data to undertake hypothesis-driven research will not be unreasonably withheld. To gain access, data requesters will need to sign a data access agreement and to confirm that data will only be used for the agreed purpose for which access was granted.

  • Conflict of interest: C. Baggott reports grants from the Health Research Council of New Zealand, during the conduct of the study; support for meeting attendance from AstraZeneca and Novartis, outside the submitted work.

  • Conflict of interest: J. Hardy reports grants from the Health Research Council of New Zealand, during the conduct of the study; travel costs from AstraZeneca, outside the submitted work.

  • Conflict of interest: J. Sparks reports grants from the Health Research Council of New Zealand, during the conduct of the study.

  • Conflict of interest: M. Holliday reports grants from the Health Research Council of New Zealand, during the conduct of the study.

  • Conflict of interest: D. Hall reports grants from the Health Research Council of New Zealand, during the conduct of the study.

  • Conflict of interest: A. Vohlidkova reports grants from the Health Research Council of New Zealand, during the conduct of the study.

  • Conflict of interest: R. Hancox reports grants from the Health Research Council of New Zealand, during the conduct of the study; support for meeting attendance from AstraZeneca and Boehringer Ingelheim, fees for lectures from Menarini, outside the submitted work.

  • Conflict of interest: M. Weatherall reports grants from the Health Research Council of New Zealand, during the conduct of the study.

  • Conflict of interest: J. Fingleton reports grants from the Health Research Council of New Zealand, during the conduct of the study; grants, personal fees for lectures and support for meeting attendance from AstraZeneca, grants and personal fees for lectures from GlaxoSmithKline, grants from Genentech, personal fees for lectures and support for meeting attendance from Boehringer Ingelheim, outside the submitted work.

  • Conflict of interest: R. Beasley reports grants from the Health Research Council of New Zealand, during the conduct of the study; grants and personal fees from AstraZeneca and GlaxoSmithKline, grants from Genentech, personal fees from Avillion and Theravance, outside the submitted work.

  • Support statement: The PRACTICAL study was funded through a programme grant (15/573) provided by the Health Research Council of New Zealand to the study sponsor, the Medical Research Institute of New Zealand (MRINZ). The MRINZ had overall responsibility for the study conduct, monitoring and data management. The randomised medications were purchased commercially. Funding information for this article has been deposited with the Crossref Funder Registry.

  • Received January 26, 2020.
  • Accepted May 17, 2020.
  • Copyright ©ERS 2020
https://www.ersjournals.com/user-licence
View Full Text

ERS Members

myERS - ERS members : log in with your myERS username and password.

INDIVIDUALS

Log in Login as an individual user.

Forgot your username or password?

LIBRARY USERS

Log in through your institution

If your library has a subscription, you may already be logged in via your IP address. Otherwise you may be able to log in via one of the following routes.
You may be able to gain access using your login credentials for your institution. Contact your library if you do not have a username and password.
If your organization uses OpenAthens, you can log in using your OpenAthens username and password. To check if your institution is supported, please see this list. Contact your library for more details.
If you think you should have access, please contact your librarian or email journals@ersnet.org

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top
View this article with LENS
Vol 56 Issue 4 Table of Contents
European Respiratory Journal: 56 (4)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Self-titration of inhaled corticosteroid and β2-agonist in response to symptoms in mild asthma: a pre-specified analysis from the PRACTICAL randomised controlled trial
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Self-titration of inhaled corticosteroid and β2-agonist in response to symptoms in mild asthma: a pre-specified analysis from the PRACTICAL randomised controlled trial
Christina Baggott, Jo Hardy, Jenny Sparks, Mark Holliday, Daniela Hall, Alexandra Vohlidkova, Robert J. Hancox, Mark Weatherall, James Fingleton, Richard Beasley
European Respiratory Journal Oct 2020, 56 (4) 2000170; DOI: 10.1183/13993003.00170-2020

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Self-titration of inhaled corticosteroid and β2-agonist in response to symptoms in mild asthma: a pre-specified analysis from the PRACTICAL randomised controlled trial
Christina Baggott, Jo Hardy, Jenny Sparks, Mark Holliday, Daniela Hall, Alexandra Vohlidkova, Robert J. Hancox, Mark Weatherall, James Fingleton, Richard Beasley
European Respiratory Journal Oct 2020, 56 (4) 2000170; DOI: 10.1183/13993003.00170-2020
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Abstract
    • Introduction
    • Methods
    • Results
    • Discussion
    • Supplementary material
    • Shareable PDF
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Asthma and allergy
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

Original Articles

  • EmPHasis-10 as a measure of quality of life in PAH
  • EmPHasis-10 health-related quality of life score predicts outcomes in PAH
  • Periostin and airway epithelial function in asthma
Show more Original Articles

Asthma

  • Cost-effectiveness of azithromycin in reducing asthma exacerbations
  • Complement C3 and allergic asthma
  • Identifying asthma phenotypes based on extrapulmonary traits
Show more Asthma

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • CME
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Submit a manuscript
  • ERS author centre

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2021 by the European Respiratory Society